Literature DB >> 22819326

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

Hasan Korkaya1, Gwang-Il Kim, April Davis, Fayaz Malik, N Lynn Henry, Suthinee Ithimakin, Ahmed A Quraishi, Nader Tawakkol, Rosemarie D'Angelo, Amanda K Paulson, Susan Chung, Tahra Luther, Hayley J Paholak, Suling Liu, Khaled A Hassan, Qin Zen, Shawn G Clouthier, Max S Wicha.   

Abstract

Although inactivation of the PTEN gene has been implicated in the development of resistance to the HER2 targeting antibody trastuzumab, the mechanisms mediating this resistance remain elusive. We generated trastuzumab resistant cells by knocking down PTEN expression in HER2 overexpressing breast cancer cell lines and demonstrate that development of trastuzumab resistance in these cells is mediated by activation of an IL6 inflammatory feedback loop leading to expansion of the cancer stem cell (CSC) population. Long term trastuzumab treatment generates highly enriched CSCs which display an EMT phenotype secreting over 100-fold more IL6 than parental cells. An IL6 receptor antibody interrupted this inflammatory feedback loop reducing the cancer stem cell population resulting in decreased tumor growth and metastasis in mouse xenographs. These studies demonstrate that trastuzumab resistance may be mediated by an IL6 inflammatory loop and suggest that blocking this loop may provide alternative strategy to overcome trastuzumab resistance.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819326      PMCID: PMC3432419          DOI: 10.1016/j.molcel.2012.06.014

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  31 in total

1.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

2.  Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.

Authors:  Dimitrios Iliopoulos; Heather A Hirsch; Guannan Wang; Kevin Struhl
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

3.  TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Authors:  Zhan Yao; Silvia Fenoglio; Ding Cheng Gao; Matthew Camiolo; Brendon Stiles; Trine Lindsted; Michaela Schlederer; Chris Johns; Nasser Altorki; Vivek Mittal; Lukas Kenner; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

4.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

5.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Authors:  Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu
Journal:  J Oncol       Date:  2010-10-12       Impact factor: 4.375

Review 7.  Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.

Authors:  Christine E Eyler; Jeremy N Rich
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

8.  Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.

Authors:  N J Sullivan; A K Sasser; A E Axel; F Vesuna; V Raman; N Ramirez; T M Oberyszyn; B M Hall
Journal:  Oncogene       Date:  2009-07-06       Impact factor: 9.867

9.  A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.

Authors:  Litian Yu; Patricia A Baxter; Horatiu Voicu; Sivashankarappa Gurusiddappa; Yijue Zhao; Adekunle Adesina; Tsz-Kwong Man; Qin Shu; Yu-Jing Zhang; Xiu-Mei Zhao; Jack M Su; Lazlo Perlaky; Robert Dauser; Murali Chintagumpala; Ching C Lau; Susan M Blaney; Pulivarthi H Rao; Hon-Chiu Eastwood Leung; Xiao-Nan Li
Journal:  Neuro Oncol       Date:  2010-02-08       Impact factor: 12.300

10.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.

Authors:  T Bachelot; I Ray-Coquard; C Menetrier-Caux; M Rastkha; A Duc; J-Y Blay
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more
  220 in total

Review 1.  Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.

Authors:  Qin Pan; Qiao Li; Shuang Liu; Ning Ning; Xiaolian Zhang; Yingxin Xu; Alfred E Chang; Max S Wicha
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

Review 2.  NF-κB signaling in cancer stem cells: a promising therapeutic target?

Authors:  K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado
Journal:  Cell Oncol (Dordr)       Date:  2015-08-29       Impact factor: 6.730

Review 3.  Identifying and targeting tumor-initiating cells in the treatment of breast cancer.

Authors:  Wei Wei; Michael T Lewis
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

4.  LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Authors:  Keshuo Ding; Zhengsheng Wu; Xiaocan Li; Youjing Sheng; Xiaonan Wang; Sheng Tan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

5.  Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.

Authors:  Satish K Noonepalle; Franklin Gu; Eun-Joon Lee; Jeong-Hyeon Choi; Qimei Han; Jaejik Kim; Maria Ouzounova; Austin Y Shull; Lirong Pei; Pei-Yin Hsu; Ravindra Kolhe; Fang Shi; Jiseok Choi; Katie Chiou; Tim H M Huang; Hasan Korkaya; Libin Deng; Hong-Bo Xin; Shuang Huang; Muthusamy Thangaraju; Arun Sreekumar; Stefan Ambs; Shou-Ching Tang; David H Munn; Huidong Shi
Journal:  Cancer Immunol Res       Date:  2017-03-06       Impact factor: 11.151

6.  HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.

Authors:  Nadire Duru; Ming Fan; Demet Candas; Cheikh Menaa; Hsin-Chen Liu; Danupon Nantajit; Yunfei Wen; Kai Xiao; Angela Eldridge; Brett A Chromy; Shiyong Li; Douglas R Spitz; Kit S Lam; Max S Wicha; Jian Jian Li
Journal:  Clin Cancer Res       Date:  2012-10-22       Impact factor: 12.531

7.  Breast cancer stem cells: we've got them surrounded.

Authors:  Hasan Korkaya; Max S Wicha
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

8.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 9.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

Review 10.  Obesity and cancer--mechanisms underlying tumour progression and recurrence.

Authors:  Jiyoung Park; Thomas S Morley; Min Kim; Deborah J Clegg; Philipp E Scherer
Journal:  Nat Rev Endocrinol       Date:  2014-06-17       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.